Eledon Pharmaceuticals (ELDN) Cash from Investing Activities (2013 - 2026)
Eledon Pharmaceuticals posted quarterly Cash from Investing Activities of $6.0 million for Q1 2026, up 53.03% year-on-year from $3.9 million in Q1 2025, and up 129.11% on a QoQ basis from -$20.5 million in Q4 2025.
Eledon Pharmaceuticals (ELDN) has 9 years of Cash from Investing Activities data on file, last reported at $6.0 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities rose 53.03% year-over-year to $6.0 million; the trailing twelve-month figure through Mar 2026 stood at $12.9 million (up 116.87% YoY), and the FY2025 full-year result was $10.8 million, up 115.35% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $6.0 million, up from -$20.5 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $15.0 million in Q2 2025 and bottomed at -$47.4 million in Q4 2024.
- The 4-year median for Cash from Investing Activities is $3.9 million (2025), against an average of -$6.2 million.
- The widest annual swing landed in 2024, when Cash from Investing Activities tumbled 570.25%; it then soared 196.9% in 2025.
- A 4-year view of Cash from Investing Activities shows it stood at $10.1 million in 2023, then sank by 570.25% to -$47.4 million in 2024, then soared by 56.81% to -$20.5 million in 2025, then surged by 129.11% to $6.0 million in 2026.
- The last three Cash from Investing Activities figures came in at $6.0 million (Q1 2026), -$20.5 million (Q4 2025), and $12.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.89 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 638.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -431.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -428.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Eledon Pharmaceuticals | 419.90 Mn | 203.87 Mn | - | 5.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.96 Mn |
| Mar 31, 2026 | 5.96 Mn |
| Dec 31, 2025 | -20.46 Mn |
| Dec 31, 2025 | -20.46 Mn |
| Sep 30, 2025 | 12.41 Mn |
| Sep 30, 2025 | 12.41 Mn |
| Jun 30, 2025 | 14.96 Mn |
| Jun 30, 2025 | 14.96 Mn |
| Mar 31, 2025 | 3.89 Mn |
| Mar 31, 2025 | 3.89 Mn |
| Dec 31, 2024 | -47.38 Mn |
| Dec 31, 2024 | -47.38 Mn |
| Sep 30, 2024 | -12.80 Mn |
| Sep 30, 2024 | -12.80 Mn |
| Jun 30, 2024 | -19.91 Mn |
| Jun 30, 2024 | -19.91 Mn |
| Mar 31, 2024 | 9.78 Mn |
| Mar 31, 2024 | 9.78 Mn |
| Dec 31, 2023 | 10.08 Mn |
| Dec 31, 2023 | 10.08 Mn |
| Sep 30, 2023 | -25.03 Mn |
| Sep 30, 2023 | -25.03 Mn |
| Jun 30, 2017 | 18.93 Mn |
| Jun 30, 2017 | 18.93 Mn |
| Mar 31, 2017 | 4.33 Mn |
| Mar 31, 2017 | 4.33 Mn |
| Dec 31, 2016 | 13,000.00 |
| Dec 31, 2016 | 13,000.00 |
| Sep 30, 2016 | -2,000.00 |
| Sep 30, 2016 | -2,000.00 |
| Jun 30, 2016 | 7,000.00 |
| Jun 30, 2016 | 7,000.00 |
| Mar 31, 2016 | -17,000.00 |
| Mar 31, 2016 | -17,000.00 |
| Dec 31, 2015 | -316,000.00 |
| Dec 31, 2015 | -316,000.00 |
| Sep 30, 2015 | -15.85 Mn |
| Sep 30, 2015 | -15.85 Mn |
| Jun 30, 2015 | -24.30 Mn |
| Jun 30, 2015 | -24.30 Mn |
| Mar 31, 2015 | -45,000.00 |
| Mar 31, 2015 | -45,000.00 |
| Sep 30, 2014 | -157,000.00 |
| Sep 30, 2014 | -157,000.00 |
| Jun 30, 2014 | -6,000.00 |
| Jun 30, 2014 | -6,000.00 |
| Mar 31, 2014 | -12,000.00 |
| Mar 31, 2014 | -12,000.00 |
| Dec 31, 2013 | -4,000.00 |
| Dec 31, 2013 | -4,000.00 |